AstraZeneca Shares Climb on Positive Saphnelo Lupus Trial Outcomes
“AstraZeneca’s stock experienced notable gains following the announcement of successful Phase III results for the subcutaneous version of Saphnelo, demonstrating…
“AstraZeneca’s stock experienced notable gains following the announcement of successful Phase III results for the subcutaneous version of Saphnelo, demonstrating…